Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Short communication

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15)

Authors: Susana Lisboa, Nuno Cerveira, Susana Bizarro, Cecília Correia, Joana Vieira, Lurdes Torres, José M Mariz, Manuel R Teixeira

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

NUP98 gene rearrangements have been reported in acute myeloid leukemia, giving rise to fusion proteins that seem to function as aberrant transcription factors, and are thought to be associated with poor prognosis.

Findings

A patient with treatment-related acute myeloid leukemia presented a t(3;11)(p11;p15) as the only cytogenetic abnormality. FISH and molecular genetic analyses identified a class 1 homeobox gene, POU1F1, located on chromosome 3p11, as the fusion partner of NUP98. In addition, we have found that the patient harbored an FLT3-ITD mutation, which most likely collaborated with the NUP98-POU1F1 fusion gene in malignant transformation.

Conclusions

We have identified POU1F1 as the NUP98 fusion partner in therapy-related AML with a t(3;11)(p11;p15). This is the first POU family member identified as a fusion partner in human cancer.
Appendix
Available only for authorised users
Literature
1.
Gough SM, Slape CI, Aplan PD: NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011, 118: 6247-6257. 10.1182/blood-2011-07-328880PubMedCentralCrossRefPubMed
2.
Nebral K, König M, Schmidt HH, Lutz D, Sperr WR, Kalwak K, Brugger S, Dworzak MN, Haas OA, Strehl S: Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica. 2005, 90: 746-752.PubMed
3.
Eklund E: The role of Hox proteins in leukemogenesis: insights into key regulatory events in hematopoiesis. Crit Rev Oncog. 2011, 16: 65-76. 10.1615/CritRevOncog.v16.i1-2.70PubMedCentralCrossRefPubMed
4.
Shaffer LG, Slovak ML, Campbell LJ: An International System for Human Cytogenetic Nomenclature. 2009, , BaselKarger Publishers.
5.
Chou WC, Chen CY, Hou HA, Lin LI, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY: Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia. 2009, 23: 1303-1310. 10.1038/leu.2009.25CrossRefPubMed
6.
Andersen B, Rosenfeld MG: POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev. 2011, 22: 2-35.
7.
Delhase M, Vergani P, Malur A, Hooghe-Peters EL, Hooghe RJ: The transcription factor Pit-1/GHF-1 is expressed in hematopoietic and lymphoid tissues. Eur J Immunol. 1993, 23: 951-955. 10.1002/eji.1830230428CrossRefPubMed
8.
Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO, Vizoso F, Perez-Fernandez R: Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest. 2010, 120: 4289-4302. 10.1172/JCI42015PubMedCentralCrossRefPubMed
9.
Ben-Batalla I, Seoane S, Macia M, Garcia-Caballero T, Gonzalez LO, Vizoso F, Perez-Fernandez R: The Pit-1/Pou1f1 transcription factor regulates and correlates with prolactin expression in human breast cell lines and tumors. Endocr Relat Cancer. 2010, 17: 73-85. 10.1677/ERC-09-0100PubMedCentralCrossRefPubMed
10.
Costoya JA, García-Barros M, Gallego R, Señarís R, Arce VM, Devesa J: Correlation of Pit-1 gene expression and Pit-1 content with proliferation and differentiation in human myeloid leukemic cells. Exp Cell Res. 1998, 245: 132-136. 10.1006/excr.1998.4232CrossRefPubMed
11.
Capelson M, Liang Y, Schulte R, Mair W, Wagner U, Hetzer MW: Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell. 2010, 140: 372-383. 10.1016/j.cell.2009.12.054PubMedCentralCrossRefPubMed
12.
Kalverda B, Pickersgill H, Shloma VV, Fornerod M: Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell. 2010, 140: 360-371. 10.1016/j.cell.2010.01.011CrossRefPubMed
13.
Xu S, Powers MA: Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. Mol Biol Cell. 2010, 21: 1585-1596. 10.1091/mbc.E09-07-0561PubMedCentralCrossRefPubMed
14.
Argiropoulos B, Humphries RK: Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007, 26: 6766-6776. 10.1038/sj.onc.1210760CrossRefPubMed
15.
Kosmider O, Moreau-Gachelin F: From mice to human: the “two-hit model” of leukemogenesis. Cell Cycle. 2006, 5: 569-570. 10.4161/cc.5.6.2577CrossRefPubMed
16.
Taketani T, Taki T, Nakamura T, Kobayashi Y, Ito E, Fukuda S, Yamaguchi S, Hayashi Y: High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia. 2010, 24: 1975-1977. 10.1038/leu.2010.207CrossRefPubMed
Metadata
Title
POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15)
Authors
Susana Lisboa
Nuno Cerveira
Susana Bizarro
Cecília Correia
Joana Vieira
Lurdes Torres
José M Mariz
Manuel R Teixeira
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-5

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

Research

Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion

Research

Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion

Research

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling

Research

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth

Research

Role of SIRT3 in the regulation of redox balance during oral carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits